Hims & Hers Health, Inc. $HIMS Shares Sold by Carnegie Investment Counsel

Key Points

• Institutional investor Carnegie Investment Counsel cut its stake in Hims & Hers by 69.3%, selling 210,575 shares in Q4 and leaving 93,334 shares valued at about $3.03 million.
• Significant insider selling occurred recently, led by COO Michael Chi's sale of 97,289 shares (~$2.40 million); insiders sold 129,889 shares (~$3.23 million) in the last three months and now own 13.71% of the stock.
• Hims & Hers reported Q4 EPS of $0.08 (vs. $0.02 estimate) and revenue of $617.8M (slightly below estimates) with revenue up 28.4% YoY; the stock trades near $19.45, carries a consensus analyst rating of "Hold" and a $31.71 average price target.

Carnegie Investment Counsel lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 69.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,334 shares of the company's stock after selling 210,575 shares during the quarter. Carnegie Investment Counsel's holdings in Hims & Hers Health were worth $3,031,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in HIMS. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at $28,000. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health during the third quarter valued at $28,000. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health during the first quarter valued at $30,000. Finally, Hilltop National Bank acquired a new position in shares of Hims & Hers Health during the third quarter valued at $35,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $19.45 on Friday. The business's 50-day moving average price is $19.72 and its 200 day moving average price is $33.39. The firm has a market cap of $4.43 billion, a P/E ratio of 38.14, a PEG ratio of 1.85 and a beta of 2.32. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health's revenue was up 28.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.11 earnings per share. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on HIMS. Bank of America raised Hims & Hers Health from an "underperform" rating to a "neutral" rating and raised their price target for the company from $12.50 to $23.00 in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a report on Tuesday, March 10th. TD Cowen lowered their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating on the stock in a research note on Friday, March 27th. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Finally, Truist Financial reiterated a "hold" rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $31.71.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares in the company, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,889 shares of company stock valued at $3,230,986 in the last three months. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.